ayuVeer®

Veerhealth Care Ltd.

CIN : L65910MH1992PLC067632

**Date: 16.11.2026**

To,
BSE Limited
Department of Corporate Services
P. J. Towers, Dalal Street,
Mumbai - 400001
**Scrip Code: 511523**

**Subject: Press Release on H1FY27 Standalone Un-Audited Financial Highlights**

Dear Sir/Ma'am,

We are enclosing herewith the press release on highlights of H1FY27 Standalone Un-Audited Financial Reports along with orders announced till now.

You are requested to take the same on record.

Thanking you.

Yours faithfully

**For Veerhealth Care limited**

BHAVIN SATISH SHAH

Digitally signed by BHAVIN SATISH SHAH
DN: c=IN, st=Maharashtra, 2.5.4.20=52ce4b69d7fdb3a90c91ddfee5a2fff6e38beb802aa3922b5f6d411414c3a576, postalCode=400092, street=Near Pawar Public School Mumbai Borivali West, pseudonym=3b96acd5-e0aa-4ffc-a665-17beba26d314, title=9128, serialNumber=ca6ec2cdac33664b7d5756748187e953db3886ae682190f7575 4ab671040ac96, o=Personal, cn=BHAVIN SATISH SHAH
Date: 2026.11.16 16:52:48 +05'30'

**Bhavin S. Shah**
**Managing Director**
**DIN: 03129574**

VeerHealth Care Ltd.
NATURE-AL DIRECTION TO REMEDIES

# Veerhealth Care Limited Reports Historical H1FY27 Results reporting 458.21% YoY growth at ₹ 47.28 Crore in Revenues from Operations & 397.96% YoY growth at ₹ 2.44 Crore in PAT

**Mumbai – 16th November, 2026: Veerhealth Care Limited (BSE: VEERHEALTH), Veerhealth Care is India's one of the fastest growing only Vegan Ayurvedic & Herbal Cosmetic Listed company.** Ayuveer, backed by Veerhealth Care's expertise in Ayurveda, specializes in crafting ayurvedic medicines and oral care products with natural ingredients. With a focus on quality and affordability, Ayuveer aims to offer an exceptional and safe daily care experience to its customers.

## H1FY27 Standalone Un-Audited Financial Highlights:

- Revenues from Operations of ₹ 47.28 Crore, YoY **growth of 458.21%**
- Total Revenues of ₹ 47.63 Crore, YoY **growth of 409.96%**
- EBITDA of ₹ 4.12 Crore, YoY **growth of 200.73%**
- Net Profit of ₹ 2.44 Crore, YoY **growth of 397.96%**

## Orders Announced till now in FY27:

1. Sample Order worth ₹10.07 Lakhs from a Company having an Indo-Canadian joint venture for Supply of Oral Care Products. An MoU has been signed with this Client for long term Business. The buyer Company is having an Indo-Canadian joint venture which is one of the world's largest suppliers of luxury amenities, serving 15,000+ hotels and 20+ airlines across 70+ countries and 45+ brands.

2. Orders from New York -based Company for supply of body care products for a value aggregating to ₹293 Lakhs.

3. Orders from one of India's Fast Moving Consumer Goods (FMCG) company for skincare products aggregating to ₹2715 Lakhs.

4. Order from India's Leading large Retail network of pharmacies and healthcare company aggregating to ₹111 Lakhs.

5. Sample Order worth around ₹15.74 Lakhs for supply of Gripe Water from an established buyer based out of Sudan.

VEERHEALTH CARE LTD. MUMBAI

**Key Highlights:**

- Veerhealth Care has received USFDA clearance, enabling exports of Drug (OTC) products to the USA and unlocking access to other international markets, in line with its "Local to Global" vision. It is one of the leading small-cap companies in India in the Food & Drug (OTC) segment with a USFDA-approved plant. Despite its size, the Company is now in the league of larger players, eligible for larger export orders. Globally, very few small-cap companies have secured USFDA plant clearance, positioning Veerhealth Care in a distinctive category.
- Discussions with a major Russian group for oral care exports has entered advanced stage; Veerhealth Care expects entry into Russian market very soon.
- Completed onboarding of Ayuveer products on Myntra, expanding e-commerce presence. Now present across Amazon, Flipkart, Nykaa, Glowroad, Jiomart, and Myntra.
- Commenced production at new facility with in-house plastic molding for packaging and backward integration.

**In Current F.Y. 2026-27 we are expecting Total Income of ₹ 105 crores with PAT of minimum ₹ 5 - 7 crores. We are expecting additional turnover of around ₹ 3-4 crores from Indo-Canadian JV client.**

**In F.Y. 2027-28 we are expecting Total Income of ₹ 156 crores with PAT of minimum ₹ 9 - 11 crores. We are expecting additional turnover of around ₹ 10 crores from Indo-Canadian JV client.**

**Commenting on the financial performance, Mr. Bhavin Shah - Managing Director of Veerhealth Care Limited, said,** "I am delighted with the progress we have made in H1FY27 by reporting **Highest ever Half Yearly Revenues from Operations of ₹ 47.28 Crore,** driven by our consistent focus on expanding our international footprint and strengthening our domestic presence. Due to ongoing Geo Political Tensions we could not deliver few of our Export Orders in Q2FY27 which we have started dispatching after easing of these tensions. **Going ahead we expect to maintain the high growth rates which we have delivered till now in this Financial Year."**

**Globally, very few small-cap companies have secured USFDA plant clearance, positioning Veerhealth Care in a distinctive category.**

**In line with its "Local to Global" ambition, Veerhealth Care is actively working towards scaling its manufacturing and export operations for products under the medical device category in the U.S. market.**

VEERHEALTH CARE LTD. MUMBAI

**Disclaimer**

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.